Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look ...
Heart disease-focused Tenaya Therapeutics falls on high volume after pricing a $60 million offering and releasing new TN-401 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback